Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

October 20, 2017

Dohmen chairs World Congress Rare Disease Market Access and Commercialization Summit

Dohmen Life Science Services (DLSS) will join pharmaceutical leaders next week in Boston for the 4th Annual World Congress Rare Disease Market Access and Commercialization Summit. The industry-focused event examines the challenges, innovations, and techniques for achieving commercial success and navigating the payer landscape.

DLSS Chief Business Development and Account Management Officer, Lynda Parker, will serve as Chairperson for the event and help lead important discussions. “We understand the critical role payer contracting plays in successful orphan drug commercialization. Being in Boston provides a great opportunity for pharma and patient advocacy leaders to collaborate to share best practices to successfully bring these much-needed therapies to market,” says Parker.

Key topics presented over the two days include reimbursement, value determinations, pricing models, and financial and clinical support initiatives and the impact they have on manufacturers, payers, patients, advocacy groups, service providers and more.

To learn more about the summit and to access the full agenda visit their website.